drugset
drugset / Trial / NCT07470710

Study on the Application of ¹⁸F-FCOB04, a MAO-B Targeted PET Imaging Agent, in Neurodegenerative Diseases

NCT07470710 ↗

Phase 0 Not yet recruiting 40 enrolled Peking Union Medical College Hospital
Non-randomizedParallel-groupOpen-labelDiagnostic

Summary

In this clinical trial, we intend to perform 18F-FCOB04 PET imaging in patients with neurodegenerative diseases to observe the brain uptake of this tracer.We will investigate the distinct imaging patterns of brain MAO-B expression in patients with various neurodegenerative diseases.Correlation analysis will be conducted between imaging findings and relevant clinical indicators.This study aims to evaluate the role of 18F-FCOB04 in the auxiliary diagnosis of neurodegenerative diseases, as well as to assess the tolerability and safety of the tracer and the imaging procedure.

Timeline

Start
2026-03-09
Primary completion
2026-12-31
Completion
2026-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject 18F-FCOB04 Unknown — Intravenous

Indications

neurodegenerative disease